The mechanism of Bu-Yang-Huan-Wu decoction in treating acute cerebral infarction by evaluating the levels of serum procalcitonin and homocysteine

Abstract:

Objective To explore the therapeutic mechanism of Bu-Yang-Huan-Wu decoction（Qi-Long-Qu-Yu mixture） in the treatment of acute cerebral infarction from the changes of serum procalcitonin（PCT）and homocysteine（Hcy）.Methods A total of 219 patients with acute cerebral infarction were selected from June 2018 to December 2020. And 128 patients with qi deficiency and blood stasis type in traditional Chinese medicine were randomly divided into control group（n=64，conventional treatment of Western medicine）and treatment group（n=64，conventional treatment of Western medicine plus Bu-Yang-Huan-Wu decoction）for clinical treatment and observation，with 4 weeks of the treatment observation. The changes of National Institutes of Health Stroke Scale（NIHSS）score and stroke-specific quality of life scale（SS-QOL） score at admission，10th day and 4th week were evaluated clinically. Serum PCT and Hcy levels were detected at the three time points，and clinical adverse reactions and laboratory adverse reactions were counted.Results Compared with before treatment，NIHSS scores of 2 groups at 4th week were significantly lower after treatment，and the NIHSS scores of treatment group were lower than that of control group，and the treatment group had lower scores than the control group（P<0.01）. Compared with before treatment，the SS-QOL scores of 2 groups at 4th week were higher than before treatment，and those of the treatment group were higher than those of the control group（P<0.01）. At 4th week，there were significant differences in Hcy and PCT of the two groups compared with before the treatment. In addition，Hcy and PCT in the treatment group were lower than those in the control group at 4th week，with statistical differences.Conclusion Bu-Yang-Huan-Wu decoction is safe and effective in the treatment of patients with acute cerebral infarction，and may improve the symptoms of neurological impairment by reducing the levels of PCT and Hcy in serum.